No approved hantavirus vaccine is expected in 2026, as all candidates remain in preclinical or early-phase development with no Phase 3 efficacy trials underway. Recent animal studies, including single-dose mRNA platforms from UTMB showing full protection against Andes virus and collaborative Moderna-Korea University work, have advanced immunogenicity data, yet these require years of human safety testing, GMP manufacturing, and regulatory review. Strain diversity and the absence of urgent funding comparable to Operation Warp Speed further constrain timelines. A major outbreak triggering emergency use authorization could accelerate progress, though current epidemiological patterns make that improbable before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% chance
$130,985 Vol.
$130,985 Vol.
Dec 30, 2026
6% chance
$130,985 Vol.
$130,985 Vol.
Dec 30, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine is expected in 2026, as all candidates remain in preclinical or early-phase development with no Phase 3 efficacy trials underway. Recent animal studies, including single-dose mRNA platforms from UTMB showing full protection against Andes virus and collaborative Moderna-Korea University work, have advanced immunogenicity data, yet these require years of human safety testing, GMP manufacturing, and regulatory review. Strain diversity and the absence of urgent funding comparable to Operation Warp Speed further constrain timelines. A major outbreak triggering emergency use authorization could accelerate progress, though current epidemiological patterns make that improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$130,985End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine is expected in 2026, as all candidates remain in preclinical or early-phase development with no Phase 3 efficacy trials underway. Recent animal studies, including single-dose mRNA platforms from UTMB showing full protection against Andes virus and collaborative Moderna-Korea University work, have advanced immunogenicity data, yet these require years of human safety testing, GMP manufacturing, and regulatory review. Strain diversity and the absence of urgent funding comparable to Operation Warp Speed further constrain timelines. A major outbreak triggering emergency use authorization could accelerate progress, though current epidemiological patterns make that improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$130,985End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No approved hantavirus vaccine is expected in 2026, as all candidates remain in preclinical or early-phase development with no Phase 3 efficacy trials underway. Recent animal studies, including single-dose mRNA platforms from UTMB showing full protection against Andes virus and collaborative Moderna-Korea University work, have advanced immunogenicity data, yet these require years of human safety testing, GMP manufacturing, and regulatory review. Strain diversity and the absence of urgent funding comparable to Operation Warp Speed further constrain timelines. A major outbreak triggering emergency use authorization could accelerate progress, though current epidemiological patterns make that improbable before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions